Molecular Partners regained the global development and commercial rights to abicipar pegol from AbbVie, according to a press release.
Abicipar, an anti-VEGF DARPin protein molecule, has undergone two phase 3 studies that have shown efficacy in treating neovascular age-related macular degeneration. It is also under investigation for the treatment of diabetic macular edema.
“There remains a significant unmet medical need for patients living with [neovascular] AMD and DME, and we remain confident in abicipar’s potential to offer these patients a differentiated treatment option over